Key result
Systemic administration of Ant34a completely silenced miR-34a myocardial expression and significantly attenuated doxorubicin-induced cardiac dysfunction, apoptosis, senescence, fibrosis, and inflammation.
Why the study?
Anthracycline cardiotoxicity is a serious clinical issue, and the cardioprotective properties of targeting miR-34a in vivo warranted evaluation.
Does miR-34a silencing with Ant34a prevent doxorubicin-induced cardiac dysfunction in a rat model?
Population
Rat model of DOXO-induced cardiotoxicity
Comparison
Systemic administration of Ant34a vs DOXO alone
Design
Animal experimental study
Authors
Loading...
MiR-34a silencing may attenuate anthracycline cardiotoxicity in preclinical models; leaves open clinical translation pending human trials.
Does miR-34a silencing with Ant34a prevent doxorubicin-induced cardiac dysfunction in a rat model?
p-value: p=<0.05
Systemic inhibition of miR-34a attenuates doxorubicin-induced cardiotoxicity in rats, suggesting a potential cardioprotective strategy for anthracycline-treated patients.
Piegari et al. (2020) studied Doxorubicin-induced cardiotoxicity (n=33). Ant34a (miR-34a inhibitor) vs. Scramble control (AntCTL) or saline was evaluated on Cardiac function (diastolic and systolic parameters) and myocardial damage markers (p=<0.05). Systemic administration of Ant34a completely silenced miR-34a myocardial expression and significantly attenuated doxorubicin-induced cardiac dysfunction, apoptosis, senescence, fibrosis, and inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: